Esther Rajavelu - Feb 1, 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Financial Officer and Chief Business Officer
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Esther Rajavelu
Stock symbol
SPRO
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/5/2024, 08:44 PM
Previous filing
Nov 15, 2023
Next filing
Nov 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +120K +39.96% $0.00 420K Feb 1, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Chief Financial Officer and Chief Business Officer